{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:29:24Z","timestamp":1791919764135,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T00:00:00Z","timestamp":1656201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.14283\/jpad.2022.63","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T05:42:32Z","timestamp":1655703752000},"page":"780-790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg\/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate"],"prefix":"10.1016","volume":"9","author":[{"given":"Claude M.","family":"Wischik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bentham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.O.","family":"Schelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10248","key":"10.14283\/jpad.2022.63_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"issue":"10113","key":"10.14283\/jpad.2022.63_bib2","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.14283\/jpad.2022.63_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"2021 Alzheimer's disease facts and figures","volume":"17","author":"Alzheimer's Association","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.63_bib4","article-title":"World Alzheimer Report 2021: Journey through the diagnosis of dementia","author":"Gauthier","year":"2021","journal-title":"Alzheimer's Disease International"},{"key":"10.14283\/jpad.2022.63_bib5","author":"Food and Drug Administration"},{"key":"10.14283\/jpad.2022.63_bib7","series-title":"Aduhelm [prescribing information]","year":"2021"},{"key":"10.14283\/jpad.2022.63_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.14283\/jpad.2022.36","article-title":"The \u2018Aducanumab Story': Will the Last Chapter Spell the End of the \u2018Amyloid Hypothesis' or Mark a New Beginning?","volume":"9","author":"Khachaturian","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2022.63_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.14283\/jpad.2022.37","article-title":"Aducanumab Trials EMERGE But Don't ENGAGE","volume":"9","author":"Schneider","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2022.63_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.14283\/jpad.2022.35","article-title":"Where Do We Go from Here?","volume":"9","author":"Petersen","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.14283\/jpad.2022.63_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0002-9440(10)64573-7","article-title":"Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease","volume":"157","author":"Mukaetova-Ladinska","year":"2000","journal-title":"Am J Pathol"},{"issue":"Pt5","key":"10.14283\/jpad.2022.63_bib12","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/brain\/awv050","article-title":"Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum","volume":"138","author":"Murray","year":"2015","journal-title":"Brain"},{"issue":"17","key":"10.14283\/jpad.2022.63_bib13","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1074\/jbc.M114.616029","article-title":"Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease","volume":"290","author":"Harrington","year":"2015","journal-title":"J Biol Chem"},{"issue":"4","key":"10.14283\/jpad.2022.63_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0000000000000133","article-title":"Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models","volume":"26","author":"Melis","year":"2015","journal-title":"Behav Pharmacol"},{"issue":"21","key":"10.14283\/jpad.2022.63_bib15","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.jmb.2018.08.010","article-title":"Cysteine-independent inhibition of Alzheimer's disease-like paired helical filament assembly by leucomethylthioninium (LMT)","volume":"430","author":"Al-Hilaly","year":"2018","journal-title":"J Mol Biol"},{"issue":"20","key":"10.14283\/jpad.2022.63_bib16","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.14283\/jpad.2022.63_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: An exploratory Phase 2 study in mild or moderate Alzheimer's disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2022.63_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"10062","key":"10.14283\/jpad.2022.63_bib19","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tauaggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, Phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.14283\/jpad.2022.63_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leucomethylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: Cohort analysis as modified primary outcome in a Phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.14283\/jpad.2022.63_bib21","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3233\/JAD-190772","article-title":"Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer's disease","volume":"72","author":"Schelter","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.14283\/jpad.2022.63_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1567205017666200224120926","article-title":"Mechanisms of anticholinesterase interference with Tau aggregation inhibitor activity in a tau-transgenic mouse model","volume":"17","author":"Riedel","year":"2020","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"10.14283\/jpad.2022.63_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jnc.15553","article-title":"Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine","volume":"160","author":"Kondak","year":"2022","journal-title":"J Neurochem"},{"issue":"11","key":"10.14283\/jpad.2022.63_bib24","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"Suppl 2","key":"10.14283\/jpad.2022.63_bib25","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"10.14283\/jpad.2022.63_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"Alzheimer's Disease Neuroimaging Initiative. What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.14283\/jpad.2022.63_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2013.282834","article-title":"Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial","volume":"311","author":"Dysken","year":"2014","journal-title":"JAMA"},{"key":"10.14283\/jpad.2022.63_bib28","author":"Food and Drug Administration"},{"key":"10.14283\/jpad.2022.63_bib29","author":"European Medicines Agency"},{"issue":"9","key":"10.14283\/jpad.2022.63_bib30","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.14283\/jpad.2022.63_bib31","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archneur.61.3.378","article-title":"Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function","volume":"61","author":"Bennett","year":"2004","journal-title":"Arch Neurol"},{"key":"10.14283\/jpad.2022.63_bib32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exptl Neurol"},{"key":"10.14283\/jpad.2022.63_bib33","author":"European Medicines Agency"},{"key":"10.14283\/jpad.2022.63_bib34","author":"Reuters"},{"key":"10.14283\/jpad.2022.63_bib35","series-title":"Monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease (CAG-00460N) \u2014 proposed decision memo","author":"National Coverage Analysis (NCA)","year":"2022"},{"issue":"894","key":"10.14283\/jpad.2022.63_bib36","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1259\/bjr.75.894.750506","article-title":"Serial brain MRI at 3\u20136 month intervals as a surrogate marker for Alzheimer's disease","volume":"75","author":"Bradley","year":"2002","journal-title":"Br J Radiol"},{"issue":"3","key":"10.14283\/jpad.2022.63_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/jnnp.55.3.190","article-title":"Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease","volume":"55","author":"Jobst","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.14283\/jpad.2022.63_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2016.5755","article-title":"Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease","volume":"74","author":"Xia","year":"2017","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.14283\/jpad.2022.63_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.14283\/jpad.2022.63_bib40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2022.63_bib41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00401-021-02294-3","article-title":"Cryo-EM structures of tau filaments from Alzheimer's disease with PET ligand APN-1607","volume":"141","author":"Shi","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.14283\/jpad.2022.63_bib42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/WAD.0b013e3181a6bebc","article-title":"Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors","volume":"23","author":"Bradford","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"10.14283\/jpad.2022.63_bib43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/joim.13244","article-title":"Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis","volume":"290","author":"Liss","year":"2021","journal-title":"J Intern Med"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:11:29Z","timestamp":1737339089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724002887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2274580724002887"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2022.63","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg\/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2022.63","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}